CN118613266A - 神经变性疾病的进展延缓和防御剂 - Google Patents
神经变性疾病的进展延缓和防御剂 Download PDFInfo
- Publication number
- CN118613266A CN118613266A CN202280088555.9A CN202280088555A CN118613266A CN 118613266 A CN118613266 A CN 118613266A CN 202280088555 A CN202280088555 A CN 202280088555A CN 118613266 A CN118613266 A CN 118613266A
- Authority
- CN
- China
- Prior art keywords
- disease
- component
- combination
- febuxostat
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022003851 | 2022-01-13 | ||
| JP2022-003851 | 2022-01-13 | ||
| PCT/JP2022/004661 WO2023135827A1 (ja) | 2022-01-13 | 2022-02-07 | 神経変性疾患の進行遅延及び防御剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118613266A true CN118613266A (zh) | 2024-09-06 |
Family
ID=87278717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280088555.9A Pending CN118613266A (zh) | 2022-01-13 | 2022-02-07 | 神经变性疾病的进展延缓和防御剂 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPWO2023135827A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613266A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023135827A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4871718A (en) * | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
| US6159942A (en) * | 1998-06-19 | 2000-12-12 | Bioenergy, Inc. | Compositions for increasing energy in vivo |
| CN104055124A (zh) * | 2013-07-15 | 2014-09-24 | 诚志生命科技有限公司 | 一种具有可持续抗疲劳功能的组合物 |
| WO2017033963A1 (ja) * | 2015-08-26 | 2017-03-02 | 株式会社スタージェン | 細胞内atp増強剤 |
| JP6867142B2 (ja) * | 2016-11-17 | 2021-04-28 | 株式会社スタージェン | パーキンソン症状改善用医薬 |
| WO2018092911A1 (ja) * | 2016-11-21 | 2018-05-24 | 株式会社スタージェン | 細胞内atp増強剤 |
| JP6966840B2 (ja) * | 2017-01-24 | 2021-11-17 | 株式会社スタージェン | 神経変性疾患の改善用医薬 |
| WO2020149218A1 (ja) * | 2019-01-18 | 2020-07-23 | 学校法人東京女子医科大学 | 老化防止剤または寿命延長剤 |
-
2022
- 2022-02-07 JP JP2023573821A patent/JPWO2023135827A1/ja active Pending
- 2022-02-07 CN CN202280088555.9A patent/CN118613266A/zh active Pending
- 2022-02-07 WO PCT/JP2022/004661 patent/WO2023135827A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023135827A1 (cg-RX-API-DMAC7.html) | 2023-07-20 |
| WO2023135827A1 (ja) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11427588B2 (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| RU2394580C2 (ru) | Способы лечения митохондриальных нарушений | |
| US8088752B2 (en) | Methods for metabolic modulation | |
| US20140212382A1 (en) | Purine monophosphate prodrugs for treatment of viral infections | |
| Montaigne et al. | Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium | |
| CN101184495B (zh) | 用于预防或降低患者中的不良作用的方法、组合物和制剂 | |
| US12194043B2 (en) | Uridine phosphorylase inhibitors to treat or prevent pulmonary disease | |
| Salvi | Protecting the myocardium from ischemic injury: a critical role for α1-adrenoreceptors? | |
| WO2014142290A1 (ja) | ピラゾール-アミド化合物およびその医薬用途 | |
| CN111655258B (zh) | 用于冷冻保存的组合物和其使用方法 | |
| CN106659701A (zh) | 用于治疗年龄相关性症状和疾病的酮基丁酸酯化合物和组合物 | |
| US8618074B2 (en) | GPCR enhanced neuroprotection to treat brain injury | |
| KR20050097537A (ko) | 당뇨병 치료제 | |
| JP2004502640A (ja) | 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンa2a受容体拮抗薬 | |
| JP2024015132A (ja) | O-環状フィトスフィンゴシン-1-フォスフェートを含むパーキンソン病の予防又は治療用組成物 | |
| CN101821227A (zh) | 激素敏感性脂酶调节剂及使用方法 | |
| KR100804622B1 (ko) | 글루코즈 내성에 영향을 미치는 약 조제에 대한 사이클릭에테르의 활용 | |
| EP3369419B1 (en) | Composition for treating diabetes | |
| WO2023135827A1 (ja) | 神経変性疾患の進行遅延及び防御剤 | |
| US20220125815A1 (en) | Synergistic bioactive compositions for enhancing cellular energy | |
| JP4096122B2 (ja) | 心臓線維芽細胞の増殖および心線維症を抑制する方法 | |
| CN104211747A (zh) | 5’-磷酸-n6-(3-羟基苯基)腺苷的制备及医药用途 | |
| US20240226131A1 (en) | 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment | |
| JP2009078977A (ja) | 心筋の小胞体ストレス抑制剤 | |
| RS66376B1 (sr) | Lečenje fabri pacijenata koji imaju određene mutacije |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20241212 Address after: Niigata Prefecture, Japan Applicant after: Guan Genwu Country or region after: Japan Applicant after: Genjin Life Sciences Co.,Ltd. Address before: Japan Applicant before: Genjin science and culture contract society Country or region before: Japan Applicant before: Guan Genwu Applicant before: Genjin Life Sciences Co.,Ltd. |
|
| TA01 | Transfer of patent application right |